BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Foralumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Foralumab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06868628-6849@assetmemo.bio
DTSTAMP:20261121T005901Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Foralumab: Phase 2 readout est. (NCT06868628)
DESCRIPTION:Foralumab\, phase 2.\nStudy: A Phase 2a Study of Foralumab Nasa
 l in Patients With Multiple System Atrophy (MSA)\nEstimated primary comple
 tion: 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 oralumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06868628
URL:https://assetmemo.bio/drug/foralumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688239-6849@assetmemo.bio
DTSTAMP:20261121T005901Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Foralumab: Phase 2 readout est. (NCT07688239)
DESCRIPTION:Foralumab\, phase 2\, Amyotrophic Lateral Sclerosis.\nStudy: Th
 e BANYAN Trial\, an ALS MyMatch Trial Evaluating Safety\, Biomarker Activi
 ty\, and Microglial Activation of Nasal Foralumab\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/for
 alumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07688239
URL:https://assetmemo.bio/drug/foralumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
